Rheumatoid Arthritis

Immunology·MeSH: Arthritis, Rheumatoid

Prevalence

800.0 / 100K

Incidence

41.0 / 100K/yr

91 drugs in development·58 companies·71 clinical trials

Drug Pipeline by Phase

Approved(26)

Drug	Company
abrilada	PFIZER INC (PFE)
amjevita	AMGEN INC (AMGN)
Brenzys (SB4)	Organon & Co. (OGN)
celecoxib	Zomedica Corp. (ZOMDF)
celecoxib	AlphaTON Capital Corp (ATON)
celecoxib	Aptinyx Inc. (APTX)
celecoxib	Miromatrix Medical Inc. (MIRO)
celecoxib	ACADIA PHARMACEUTICALS INC (ACAD)
Cortrophin Gel	ANI PHARMACEUTICALS INC (ANIP)
diclofenac	Miromatrix Medical Inc. (MIRO)
Hadlima (SB5)	Organon & Co. (OGN)
indocin	Assertio Holdings, Inc. (ASRT)
indocin	Zyla Life Sciences (ZCOR)
INDOCIN (suppositories and oral suspension)	Assertio Holdings, Inc. (ASRT)
INDOCIN Suppositories	Assertio Holdings, Inc. (ASRT)
indomethacin	Amneal Pharmaceuticals, Inc. (AMRX)
indomethacin	Mylan II B.V. (MYL)
meloxicam	Mylan II B.V. (MYL)
methotrexate	ELITE PHARMACEUTICALS INC /NV/ (ELTP)
Olumiant	ELI LILLY & Co (LLY)
Olumiant®	ELI LILLY & Co (LLY)
Otrexup	Assertio Holdings, Inc. (ASRT)
Purified Cortrophin Gel	ANI PHARMACEUTICALS INC (ANIP)
Renflexis (SB2)	Organon & Co. (OGN)
tofidence	BIOGEN INC. (BIIB)
xeljanz xr	PFIZER INC (PFE)

Phase 3(7)

Drug	Company
abx464	Abivax SA (ABVX)
ABX464	Abivax SA (ABVX)
BGB-45035	BeOne Medicines Ltd. (ONC)
leflunomide	Sanofi (SNY)
leflunomide	Sanofi (SNYNF)
Lutikizumab	AbbVie Inc. (ABBV)
tc99m tilmanocept	NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB)

Phase 2(24)

Drug	Company
Abiprubart	Kiniksa Pharmaceuticals International, plc (KNSA)
allogeneic nk cells	Artiva Biotherapeutics, Inc. (ARTV)
allonk	Artiva Biotherapeutics, Inc. (ARTV)
amt-101	Applied Molecular Transport Inc. (AMTI)
AZD1163	ASTRAZENECA PLC (AZN)
BGB-45035	Crinetics Pharmaceuticals, Inc. (CRNX)
cenplacel-l	Celularity Inc. (CELU)
eq121	EQRx, Inc. (EQRX)
hydroxychloroquine	Incannex Healthcare Inc. (IXHL)
ihl-675a	Incannex Healthcare Inc. (IXHL)
imvotamab	IGM Biosciences, Inc. (IGMS)
isomyosamine	Q/C TECHNOLOGIES, INC. (QCLS)
ly3541860	ELI LILLY & Co (LLY)
ly3871801	ELI LILLY & Co (LLY)
natrunix	XBiotech Inc. (XBIT)
ocadusertib	RIGEL PHARMACEUTICALS INC (RIGL)
r552	RIGEL PHARMACEUTICALS INC (RIGL)
rapcabtagene autoleucel	Novartis AG (NVS)
rapcabtagene autoleucel	Novartis AG (NVS)
Ravagalimab	AbbVie Inc. (ABBV)
sar441566	Sanofi (SNY)
SAR441566	Sanofi (SNY)
spy002-072	Spyre Therapeutics, Inc. (SYRE)
SPY072	Spyre Therapeutics, Inc. (SYRE)

Phase 1(9)

Drug	Company
ly4213663	ELI LILLY & Co (LLY)
pit565	Novartis AG (NVS)
pit565	Novartis AG (NVS)
plamotamab	Xencor Inc (XNCR)
prula-cel	Adicet Bio, Inc. (ACET)
raphael's formula	Raphael Pharmaceutical Inc. (RAPH)
sbt777101	Sonoma Pharmaceuticals, Inc. (SNOA)
sbt777101	SAB BIOTHERAPEUTICS, INC. (SABS)
vyn202	VYNE Therapeutics Inc. (VYNE)

Preclinical(12)

Drug	Company
CM6336	CalciMedica, Inc. (CALC)
CPI-182	Corvus Pharmaceuticals, Inc. (CRVS)
epidiferphane	UNITED CANNABIS CORP (CNAB)
kl-009	Luckwel Pharmaceuticals Inc. (LKYM)
kl-2120	Luckwel Pharmaceuticals Inc. (LKYM)
L.E.A.P.S.	CEL SCI CORP (CVM)
L.E.A.P.S. (Ligand Epitope Antigen Presentation System)	CEL SCI CORP (CVM)
labp-69	Landos Biopharma, Inc. (LABP)
phoenix auto	Phoenix Life Sciences International Limited. (PLSI)
ra product candidate	Raphael Pharmaceutical Inc. (RAPH)
rpi-78m	NUTRA PHARMA CORP (NPHC)
rt-105	Rani Therapeutics Holdings, Inc. (RANI)

Unknown(3)

Drug	Company
orencia	BRISTOL MYERS SQUIBB CO (BMY)
TCR discovery collaboration (non-exclusive agreements)	Adaptive Biotechnologies Corp (ADPT)
tnf-α antagonists	HCW Biologics Inc. (HCWB)

BLA Filed(1)

Drug	Company
m923	MOMENTA PHARMACEUTICALS INC (MNTA)

Phase 2/Phase 3(1)

Drug	Company
imvt-1402	Roivant Sciences Ltd. (ROIV)

Phase 4(8)

Drug	Company
Anti-Tumor Necrosis Factor Alpha Drug	Galapagos NV (GLPG)
bms-986454	BRISTOL MYERS SQUIBB CO (BMY)
DPP-4 inhibitor	ELI LILLY & Co (LLY)
Filgotinib	Galapagos NV (GLPG)
SGLT2 inhibitor	ELI LILLY & Co (LLY)
telitacicept	GH Research PLC (GHRS)
tnf inhibitor	ELI LILLY & Co (LLY)
tocilizumab	GH Research PLC (GHRS)

BioSniper tracks 91 drugs in development for Rheumatoid Arthritis across 58 companies.

There are 71 clinical trials targeting Rheumatoid Arthritis tracked by BioSniper.

The estimated prevalence of Rheumatoid Arthritis is approximately 800.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.